Identifying Elevated Neuroinflammatory Proteomic Markers in Cerebrospinal Fluid From COVID-19

Paper Summary

Identifying Elevated Neuroinflammatory Proteomic Markers in Cerebrospinal Fluid From COVID-19

In an article published in BMC Neurology, Shelli Farhadian and her Yale School of Medicine colleagues utilized IsoPlexis’ Functional Proteomics to research the case of a SARS-CoV-2 positive patient who initially presented with neurological rather than respiratory symptoms.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this Paper Summary we discuss:

Case presentation: neuroinflammation due to COVID-19

Functional proteomics reveals mechanisms in a new clinical presentation for COVID-19

Proteomic markers for neuroinflammation in COVID-19

Summary_Identifying-Elevated-Neuroinflammatory-Proteomic-Markers-in-Cerebrospinal-Fluid-From-COVID-19_IsoPlexis

A Deeper Look

More about this Paper Summary

Measuring Inflammatory Cytokines in Both CSF and Plasma Samples with Functional Proteomics

The relationship between SARS-CoV-2 and the CNS is unclear, but CNS abnormalities appeared in both SARS and MERS cases from 2002-2004 and 2014, respectively.

IsoPlexis’ highly multiplexed cytokine assay used in this study is helping provide the necessary cellular-level data to reveal critical insights for mechanisms of neuroinflammation due to SARS-CoV-2 infection.

Download this Paper Summary to learn more!

Get the Paper Summary

Back to the Top